Maravai LifeSciences Holdings Inc
MRVI2.880USD
+0.070+2.49%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
416.49MCap. mercado
PérdidaP/E TTM
Más Datos de Maravai LifeSciences Holdings Inc Compañía
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Información de la empresa
Símbolo de cotizaciónMRVI
Nombre de la empresaMaravai LifeSciences Holdings Inc
Fecha de salida a bolsaNov 20, 2020
Director ejecutivoMr. Bernd Brust
Número de empleados570
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 20
Dirección10770 Wateridge Circle Suite 200
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92121
Teléfono18585460004
Sitio Webhttps://www.maravai.com/
Símbolo de cotizaciónMRVI
Fecha de salida a bolsaNov 20, 2020
Director ejecutivoMr. Bernd Brust
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
335.06K
+0.72%
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
199.91K
+80.47%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
Dr. Murali K. Prahalad, Ph.D.
Dr. Murali K. Prahalad, Ph.D.
Independent Director
Independent Director
154.61K
+136.16%
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
+182.23%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
75.77K
-54.05%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
335.06K
+0.72%
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
199.91K
+80.47%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
North America
29.27M
62.47%
Asia Pacific
10.56M
22.53%
Europe, the Middle East and Africa
6.88M
14.68%
Latin and Central America
146.00K
0.31%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
GTCR Golder Rauner, LLC
13.93%
12 West Capital Management, L.P.
8.65%
The Vanguard Group, Inc.
6.48%
BlackRock Institutional Trust Company, N.A.
5.81%
Braidwell LP
5.77%
Otro
59.35%
Accionistas
Accionistas
Proporción
GTCR Golder Rauner, LLC
13.93%
12 West Capital Management, L.P.
8.65%
The Vanguard Group, Inc.
6.48%
BlackRock Institutional Trust Company, N.A.
5.81%
Braidwell LP
5.77%
Otro
59.35%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
29.38%
Hedge Fund
26.51%
Investment Advisor/Hedge Fund
16.15%
Private Equity
13.93%
Individual Investor
6.19%
Corporation
4.75%
Research Firm
3.98%
Pension Fund
0.20%
Bank and Trust
0.16%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
2023Q3
641
137.53M
104.23%
-17.92M
2023Q2
646
129.68M
98.32%
-22.48M
2023Q1
633
130.54M
99.07%
-18.12M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
GTCR Golder Rauner, LLC
20.15M
14%
--
--
Mar 31, 2025
12 West Capital Management, L.P.
12.52M
8.7%
+930.00K
+8.02%
Mar 31, 2025
The Vanguard Group, Inc.
11.64M
8.08%
-162.48K
-1.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.36M
5.81%
-121.20K
-1.43%
Mar 31, 2025
Braidwell LP
8.35M
5.8%
--
--
Mar 31, 2025
Hudson View Capital LLC
6.87M
4.77%
+6.87M
--
May 21, 2025
Mackenzie Investments
6.11M
4.25%
-69.09K
-1.12%
Mar 31, 2025
Renaissance Technologies LLC
4.11M
2.86%
+138.50K
+3.49%
Mar 31, 2025
Mirabella Financial Services LLP
3.74M
2.6%
+3.74M
--
Mar 31, 2025
Point72 (DIFC) Ltd
1.56M
1.08%
+561.00
+0.04%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
Research Affiliates Deletions ETF
0.71%
Royce Quant Small-Cap Quality Value ETF
0.41%
Global X Genomics & Biotechnology ETF
0.34%
iShares Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
First Trust Small Cap Core Alphadex Fund
0%
Ver más
Research Affiliates Deletions ETF
Proporción0.71%
Royce Quant Small-Cap Quality Value ETF
Proporción0.41%
Global X Genomics & Biotechnology ETF
Proporción0.34%
iShares Biotechnology ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.02%
Schwab U.S. Small-Cap ETF
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
First Trust Small Cap Core Alphadex Fund
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
